Bepanthen Versus Cetomacrogol in Epidermal Growth Factor Receptor Inhibitors (EGFRI) (BeCet)
This study has been completed.
Christine B Boers-Doets
Information provided by (Responsible Party):
Christine B Boers-Doets, Waterland Hospital
First received: June 2, 2010
Last updated: March 14, 2017
Last verified: March 2017
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study has been completed.|
|Study Completion Date:||March 2017|
|Primary Completion Date:||December 2016 (Final data collection date for primary outcome measure)|
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Clabbers JM, Boers-Doets CB, Gelderblom H, Stijnen T, Lacouture ME, van der Hoeven KJ, Kaptein AA. Xerosis and pruritus as major EGFRI-associated adverse events. Support Care Cancer. 2016 Feb;24(2):513-21. doi: 10.1007/s00520-015-2781-y.